Table 2:
Concurrent validity of LURN SI-29 subscales with Validated Instruments
| Females | Males | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Validated PRO | LURN SI-29 Scale | B (SE) | 95% CI | β | p-value | B (SE) | 95% CI | β | p-value |
| AUA-SI (n=396 males, 328 females) | Intercept | 1.77 (0.49) | 0.81–2.74 | 0.00 | <.001 | 0.69 (0.61) | −.50–1.89 | 0.00 | 0.255 |
| Incontinence (per 10 unit increase) | 0.45 (0.15) | 0.15–0.76 | 0.13 | 0.004 | 0.09 (0.38) | −.65–0.83 | 0.01 | 0.802 | |
| Bladder Pain (per 10 unit increase) | 0.43 (0.18) | 0.08–0.78 | 0.10 | 0.016 | 0.93 (0.18) | 0.58–1.28 | 0.18 | <.001 | |
| Voiding Difficulty (per 10 unit increase) | 2.11 (0.16) | 1.79–2.43 | 0.51 | <.001 | 1.92 (0.12) | 1.69–2.15 | 0.54 | <.001 | |
| Urgency (per 10 unit increase) | 0.45 (0.11) | 0.23–0.67 | 0.19 | <.001 | 0.89 (0.12) | 0.66–1.12 | 0.28 | <.001 | |
| Nocturia (per 10 unit increase) | 0.37 (0.08) | 0.22–0.52 | 0.18 | <.001 | 0.40 (0.08) | 0.24–0.56 | 0.16 | <.001 | |
| GUPI (n=331 males, 250 females) | Intercept | 3.11 (0.70) | 1.73–4.49 | 0.00 | <.001 | 2.58 (0.79) | 1.03–4.14 | 0.00 | 0.001 |
| Incontinence (per 10 unit increase) | 0.65 (0.22) | 0.21–1.10 | 0.16 | 0.004 | 1.45 (0.60) | 0.27–2.64 | 0.11 | 0.016 | |
| Bladder Pain (per 10 unit increase) | 2.08 (0.27) | 1.56–2.60 | 0.39 | <.001 | 2.43 (0.23) | 1.98–2.88 | 0.47 | <.001 | |
| Voiding Difficulty (per 10 unit increase) | 1.09 (0.24) | 0.63–1.56 | 0.21 | <.001 | 0.69 (0.15) | 0.39–0.99 | 0.20 | <.001 | |
| Urgency (per 10 unit increase) | 0.75 (0.16) | 0.44–1.06 | 0.26 | <.001 | 0.57 (0.16) | 0.26–0.88 | 0.17 | <.001 | |
| Nocturia (per 10 unit increase) | 0.07 (0.11) | −.15–0.29 | 0.03 | 0.526 | 0.25 (0.11) | 0.03–0.46 | 0.09 | 0.026 | |
| UI Severity Score (LUTS Tool, n=388 males, 305 females) | Intercept | 1.20 (0.17) | 0.87–1.53 | 0.00 | <.001 | 0.77 (0.17) | 0.45–1.10 | 0.00 | <.001 |
| Incontinence (per 10 unit increase) | 0.68 (0.06) | 0.57–0.80 | 0.52 | <.001 | 1.02 (0.11) | 0.81–1.23 | 0.41 | <.001 | |
| Bladder Pain (per 10 unit increase) | 0.04 (0.06) | −.09–0.16 | 0.02 | 0.578 | −.00 (0.05) | −.10–0.09 | −.00 | 0.927 | |
| Voiding Difficulty (per 10 unit increase) | 0.22 (0.06) | 0.11–0.33 | 0.14 | <.001 | 0.15 (0.03) | 0.08–0.21 | 0.18 | <.001 | |
| Urgency (per 10 unit increase) | 0.27 (0.04) | 0.19–0.34 | 0.31 | <.001 | 0.23 (0.03) | 0.17–0.29 | 0.33 | <.001 | |
| Nocturia (per 10 unit increase) | −.00 (0.03) | −.06–0.05 | −.01 | 0.878 | −.01 (0.02) | −.06–0.03 | −.02 | 0.608 | |
| PFDI-20 (345 females) | Intercept | 6.41 (4.13) | −1.7–14.5 | 0.00 | 0.121 | ||||
| Incontinence (per 10 unit increase) | 4.02 (1.34) | 1.39–6.65 | 0.15 | 0.003 | |||||
| Bladder Pain (per 10 unit increase) | 9.12 (1.49) | 6.19–12.1 | 0.27 | <.001 | |||||
| Voiding Difficulty (per 10 unit increase) | 10.4 (1.39) | 7.70–13.2 | 0.30 | <.001 | |||||
| Urgency (per 10 unit increase) | 5.66 (0.93) | 3.84–7.49 | 0.29 | <.001 | |||||
| Nocturia (per 10 unit increase) | −.23 (0.65) | −1.5–1.05 | −.01 | 0.727 | |||||
Note: LURN SI-29 = Lower Urinary Tract Dysfunction Research Network Symptom Index-29; EFA: Exploratory factor analysis; PRO: Patient reported outcome; AUA-SI: American Urological Association Symptom Index GUPI: Genitourinary Pain Index; PFDI-20: Pelvic Floor Distress Inventory-20. B and β represent unstandardized and standardized coefficients, respectively. Unstandardized coefficients (B) can be interpreted as the change in the raw validated PRO per 10 unit increase in the LURN SI-29 scale on its original 0–100 scale. Standardized coefficients (β) represent effect size on the standard deviation scale, i.e. the change validated PRO standard deviations per standard deviation change in the LURN SI-29 scale.